A detailed history of Simplex Trading, LLC transactions in Capricor Therapeutics, Inc. stock. As of the latest transaction made, Simplex Trading, LLC holds 17,169 shares of CAPR stock, worth $171,518. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,169
Previous 25,197 31.86%
Holding current value
$171,518
Previous $171,000 52.63%
% of portfolio
0.0%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024

SELL
$4.63 - $7.09 $37,169 - $56,918
-8,028 Reduced 31.86%
17,169 $81,000
Q1 2024

Apr 25, 2024

SELL
$3.61 - $6.88 $63,330 - $120,695
-17,543 Reduced 41.05%
25,197 $171,000
Q4 2023

Feb 02, 2024

BUY
$2.71 - $5.08 $16,148 - $30,271
5,959 Added 16.2%
42,740 $208,000
Q3 2023

Nov 01, 2023

BUY
$3.42 - $7.85 $91,091 - $209,084
26,635 Added 262.52%
36,781 $125,000
Q2 2023

Aug 04, 2023

BUY
$3.76 - $5.05 $38,148 - $51,237
10,146 New
10,146 $48,000
Q4 2022

Feb 02, 2023

SELL
$3.36 - $6.55 $185,424 - $361,468
-55,186 Reduced 79.83%
13,943 $53,000
Q3 2022

Nov 04, 2022

BUY
$3.61 - $6.08 $189,626 - $319,370
52,528 Added 316.41%
69,129 $414,000
Q2 2022

Aug 03, 2022

BUY
$2.89 - $4.51 $26,241 - $40,950
9,080 Added 120.73%
16,601 $57,000
Q1 2022

May 02, 2022

SELL
$2.83 - $5.68 $78,589 - $157,733
-27,770 Reduced 78.69%
7,521 $25,000
Q4 2021

Feb 23, 2022

BUY
$2.89 - $4.16 $53,265 - $76,672
18,431 Added 109.32%
35,291 $103,000
Q2 2021

Aug 12, 2021

BUY
$3.16 - $5.72 $38,649 - $69,961
12,231 Added 264.23%
16,860 $86,000
Q1 2021

Apr 26, 2021

BUY
$3.63 - $7.93 $16,803 - $36,707
4,629 New
4,629 $21,000
Q3 2020

Oct 14, 2020

SELL
$4.08 - $9.81 $16,499 - $39,671
-4,044 Closed
0 $0
Q2 2020

Jul 13, 2020

BUY
$1.0 - $8.5 $4,044 - $34,374
4,044 New
4,044 $18,000

Others Institutions Holding CAPR

About CAPRICOR THERAPEUTICS, INC.


  • Ticker CAPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,346,200
  • Market Cap $243M
  • Description
  • Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...
More about CAPR
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.